Who is sponsoring NCT07022457?

NCT07022457 is sponsored by Pierre Fabre Ltd.

What drugs are being tested in NCT07022457?

Interventions in NCT07022457: Encorafenib + Binimetinib.

What condition does NCT07022457 study?

NCT07022457 studies Metastatic Melanoma, BRAF V600 Mutation Positive.

Is NCT07022457 still recruiting?

NCT07022457 is currently active, enrolled. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT07022457: UK-EnBiRiM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

Active, enrolled Last updated 13 April 2026

What this trial tests

trial testing Encorafenib + Binimetinib in Metastatic Melanoma, BRAF V600 Mutation Positive in 50 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

31 July 2025

Primary endpoint
13 January 2028

13 January 2028

Quick facts

Lead sponsor	Pierre Fabre Ltd
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	50
Start date	31 July 2025
Primary completion	13 January 2028
Estimated completion	13 January 2028
Sites	7 locations across United Kingdom

Drugs / interventions tested

Encorafenib + Binimetinib (encorafenib-binimetinib) — full drug profile →

Conditions studied

Metastatic Melanoma, BRAF V600 Mutation Positive — all drugs for Metastatic Melanoma, BRAF V600 Mutation Positive →

Sponsor

Pierre Fabre Ltd

Who can join

18 and older, any sex, with Metastatic Melanoma, BRAF V600 Mutation Positive. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective longitudinal multi-centre observational study conducted in the United Kingdom, in patients with metastatic cutaneous BRAF V600 mutation-positive melanoma assigned to receive encorafenib and binimetinib. The aim of this study is to learn about how encorafenib and binimetinib perform, patients' experiences of using them, and how they might affect patient's quality of life, in the real world, when these treatments are prescribed by doctors instead of in a clinical trial. Participants will complete electronic data entry via questionnaires over a 24-month period. Site research teams will also complete electronic data entry using participants' medical records over a 24-month period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Encorafenib + Binimetinib

Trials testing the same drug.

NCT05767879 — (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma · Phase 2 · unknown
NCT05097378 — Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07022457 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pierre Fabre Ltd
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07022457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing